ArticleCase reports in hematology2019
Efficacy of Omalizumab in Indolent Systemic Mastocytosis.
Article in Case reports in hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- A successful treatment of urticaria pigmentosa with omalizumab in a pediatric patient: a case report.AME case reports · 2026Article
- Allergen Immunotherapy: Pitfalls, Perks and Unexpected Allies.International journal of molecular sciences · 2025Review
- Article
- Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes.Current allergy and asthma reports · 2024Review
- Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.Italian journal of pediatrics · 2023Article
- Case report: The devil was hidden in the mastocytes - an unusually fulminant case of indolent systemic mastocytosis in a 45-year-old patient, missed for almost 20 years.Frontiers in immunology · 2023Article
- Dental management of a patient with systemic mastocytosis.BMJ case reports · 2022Article
- Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.The Journal of allergy and clinical immunology · 2021Article
- Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis.International journal of molecular sciences · 2021Review
- Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.Naunyn-Schmiedeberg's archives of pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs. Omalizumab is an established, labelled therapy for allergic asthma and chronic urticaria, but its experience in the efficacy of SM is limited.
methodsA retrospective analysis of 6 patients diagnosed with indolent SM treated with omalizumab at St. Michael's Hospital between 2009 and 2018 is described. Reported frequency of anaphylaxis, baseline and follow-up tryptase levels, and SM-related symptoms were captured to measure the control of the disease.
resultsOf the 5 patients who had experienced unprovoked anaphylaxis prior to treatment with omalizumab, 3 had no further episodes of anaphylaxis following initiation of omalizumab, while the remaining 2 patients had milder multisystem reactions. Significant improvement in cutaneous symptoms was also observed.
conclusionThese data suggest that omalizumab provides benefit to patients with SM who remain highly symptomatic in spite of treatment with conventional therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.